RBC Capital raised the firm’s price target on Insmed (INSM) to $106 from $99 and keeps an Outperform rating on the shares. The company’s pulmonary arterial hypertension – PAH – data came in as a “home-run” scenario, with PVR – pulmonary vascular resistance – and 6MWD – six-minute walk distance coming in above even the firm’s bullish outlook as well as markedly above key competitors, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $102 from $90 at Morgan Stanley
- Mizuho ups Insmed target on ‘grand slam’ PAH data
- Buy Rating on Insmed Driven by Promising Phase 2 Results and Strategic Phase 3 Approach for PAH Treatment
- Insmed price target raised to $109 from $94 at BofA
- Insmed price target raised to $120 from $90 at H.C. Wainwright